# reload+after+2024-01-22 08:45:50.937984
address1§47 Thorndike Street
address2§Suite B1-1
city§Cambridge
state§MA
zip§02141
country§United States
phone§617 714 0360
website§https://www.leaptx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase I clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
fullTimeEmployees§44
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Douglas E. Onsi J.D.', 'age': 54, 'title': 'CFO, General Counsel, Treasurer & Secretary, President, CEO & Director', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 1041295, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Augustine J. Lawlor', 'age': 66, 'title': 'Chief Operating Officer', 'yearBorn': 1957, 'fiscalYear': 2022, 'totalPay': 713565, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Cynthia A. Sirard', 'age': 53, 'title': 'Chief Medical Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 708645, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jason S. Baum Ph.D.', 'age': 44, 'title': 'Chief Scientific Officer', 'yearBorn': 1979, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': "Mr. Mark  O'Mahony", 'age': 52, 'title': 'Chief Manufacturing Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Christine M. Granfield', 'age': 55, 'title': 'VP and Head of Regulatory Affairs & Quality', 'yearBorn': 1968, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.56
currency§USD
dateShortInterest§1702598400
forwardEps§-2.25
pegRatio§0.4
exchange§NCM
quoteType§EQUITY
shortName§Leap Therapeutics, Inc.
longName§Leap Therapeutics, Inc.
firstTradeDateEpochUtc§1485354600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§9c2a03e8-27dc-34be-8377-0c5e52ed941b
gmtOffSetMilliseconds§-18000000
targetHighPrice§21.0
targetLowPrice§7.0
targetMeanPrice§13.7
targetMedianPrice§12.0
recommendationMean§1.8
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§7.383
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
